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RISK OF MYOCARDIAL INFARCTION WITH USE OF SELECTED 
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
IN SPONDYLOARTHRITIS PATIENTS 
MAUREEN DUBREUIL 
ABSTRACT 
Background: Spondyloarthritis (SpA) is associated with increased risk of 
myocardial infarction (MI); the risk may be due to the underlying inflammatory 
disease, or also due to medications that increase MI risk, such as certain non-
steroidal anti-inflammatory drugs (NSAIDs). 
 
Objectives: 
1. To describe the risk of myocardial infarction (MI) among patients with 
spondyloarthritis who are prescribed NSAIDs 
2. To compare the pattern of MI risk with specific NSAID use among 
spondyloarthritis patients with the pattern of risk among patients with 
osteoarthritis (OA) 
 
Methods:  Nested case-control studies were performed using 1994–2015 data 
from The Health Improvement Network (THIN).  Underlying cohorts included 
adult patients with incident SpA or OA had >1 NSAID prescriptions and no history 
of MI.  In each cohort, we matched cases of incident MI to four controls without 
MI.   NSAID use was categorized as: (A) current (prescription end date 0–180 
  vi 
days prior to index date), (B) recent (181–365 days), or (C) remote (>365 days).  
We performed conditional logistic regression to compare the odds of current or 
recent NSAID use relative to remote use of any NSAID, considering diclofenac 
and naproxen specifically.   
 
Results: Within the SpA cohort of 8140 and the OA cohort of 244,399, there were 
115 and 6287 MI cases, respectively. After adjustment, among SpA subjects, 
current diclofenac use was associated with an OR of 3.05 (95% CI 1.48–6.29; 
Table 2) for MI.  Naproxen use was not associated with any increase (adjusted 
OR 1.25, 95% CI 0.56–2.78). A ratio of ORs for SpA/diclofenac relative to 
OA/diclofenac was 2.35 (1.10–4.90). 
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THESIS 
 
Background/Introduction 
Risk of myocardial infarction (MI) is increased in several systemic rheumatic 
diseases including rheumatoid arthritis, psoriatic arthritis and other forms of 
inflammatory arthritis of the spine (spondyloarthritis; SpA).1–4  Reasons for this 
increased risk are likely multifactorial, including a greater prevalence of traditional 
cardiovascular risk factors, system-wide inflammation, and use of medications 
that may predispose to MI.5–9  While some risk factors (genetics) cannot be 
changed, other modifiable risk factors, specifically medication selection, offer an 
opportunity to prevent morbidity and reduce the premature mortality associated 
with SpA.  
 
Nonsteroidal anti-inflammatory drugs (NSAIDs), are currently indicated as first-
line treatment for SpA of the spine, and for psoriatic arthritis.10–12  While NSAIDs 
may provide relief from pain and stiffness associated with SpA, their use may be 
associated with risk of adverse events such as MI.  In particular, several NSAIDs 
that selectively inhibit the cyclooxygenase-2 (COX-2) enzyme were withdrawn 
from the market when their cardiovascular risk was publicly recognized.  
Although drugs with predominantly COX-2 inhibition have been incriminated and 
limited or removed from the market, NSAIDs with relatively lower COX-2 
inhibition (“nonselective NSAIDs”) remain on the market.  In fact, the top three 
NSAIDs, diclofenac, naproxen and ibuprofen account for more than 12 million 
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prescriptions annually in the United Kingdom.13   
 
In people without known cardiovascular disease, several nonselective NSAIDs 
have been shown to increase risk of several major cardiovascular events in a 
dose-dependent fashion.  High dose diclofenac has been associated with a 41% 
increase in risk, and high dose ibuprofen use is also likely associated with an 
increased risk, though this failed to reach statistical significance in meta-analysis 
(ARR 1.44, 95% CI 0.89–2.33).14  Naproxen, on the other hand, did not have an 
increased risk (ARR 0.93, 95% CI 0.69–1.27), suggesting individual drug 
differences exist, rather than there being a class effect.  The proposed 
mechanisms for the differences in effects include the relative degree of COX-2 
enzyme inhibition (rather than the absolute degree of inhibition), as well as drug 
half-life and drug-specific effects on platelet inhibition. 
 
Despite the evidence of cardiovascular risk in the general population, the 
cardiovascular effects of NSAIDs have not been fully studied in persons with 
systemic rheumatic diseases.  The hypothesis for this study was that that MI risk 
with specific NSAIDs would follow a similar pattern in SpA patients to the pattern 
in the general population, but that risk would be greater in SpA with each drug, 
because the systemic inflammation in SpA also contributes to risk of MI.  
However, a competing theory suggests that NSAID use in inflammatory arthritis 
may protect against adverse cardiovascular events by reducing systemic 
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inflammation which itself is a risk factor for MI.  For this reason, we examined the 
risk of MI associated with use of NSAIDs in SpA patients, and also assessed this 
risk among patients with osteoarthritis (OA) separately, to compare the pattern of 
risk between the two diseases.   
 
Methods 
We performed a nested case-control study using 1994–2015 data from The 
Health Improvement Network (THIN), a database of medical records from over 
600 general practitioners in the United Kingdom.   THIN currently contains data 
on over 11 million unique individuals, covering more than 6% of the UK 
population.  
 
THIN contains systematically and prospectively recorded data collected by GPs 
on demographics, diagnoses, consultation rates, referrals, hospitalizations, 
laboratory test results, and prescriptions among patients covered in the practices. 
Diagnoses are organized according to the Read classification,15 which is akin to 
the ICD classification used in the US and elsewhere.  Prescription data include 
the dose, strength and formulation of medications, and medications are 
categorized according to the drug dictionary, Multilex.  Quality control checks are 
done regularly, and this database has been validated for several pharmaco-
epidemiologic studies as well as for MI as an outcome.16 
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Rationale for case-control study design.  The effect of NSAIDs on increasing risk 
of MI is theoretically short; with onset occurring within hours, and the effect 
lasting only up to four days following discontinuation of the drug.  For this reason, 
a case-control study design was selected, with the exposure of greatest interest 
being current use of an NSAID on the index date.  This design has the advantage 
of capturing the most recent NSAID prescription, and therefore greater likelihood 
of correctly classifying NSAID exposure among cases and controls.   Although 
many patients use NSAIDs regularly or continuously, the specific NSAID used 
may change over time.  In one study of administrative and prescription records 
for members of a large health plan, NSAID switches occurred in 15% of patients 
following the initial prescription, most commonly due to lack of efficacy and side 
effects.17  Additionally, MI cases, while “common”, occur in under 1% of patients, 
thus the case-control study will maximize the power of these relatively infrequent 
cases by including all of them (within the eligible cohort).  Because the primary 
goal of this work was to compare the relative safety of NSAIDs, and inform 
shared decision making regarding NSAID selection in clinical practice, we 
elected to use a study design that maximizes the likelihood of correct exposure 
classification, namely the case-control design with assessment of the most 
recent NSAID prescription.    
 
Underlying cohort establishment.  We identified adult patients, aged 18–89 years 
who had a diagnosis of ankylosing spondylitis (AS) or psoriatic arthritis (PsA), 
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two forms of spondyloarthritis (SpA) in THIN, after at least 12 months’ enrollment 
in the database without such a diagnosis (incident SpA cohort).  Diagnosis was 
established using Read codes documented by the patient’s GP.  In previous 
studies, a Read code alone for PsA was found to have a positive predictive value 
(PPV) of 85% and the PPV of a single AS Read code was 72%.18–19  As a control 
condition, we also identified a cohort of adults with osteoarthritis (OA, any site) 
documented by the GP. While the PPV of an OA diagnosis has not been 
assessed in THIN, the high disease prevalence makes it likely PPV will be high.  
Subjects were excluded if they had any history of MI to allow assessment of 
incident MI cases.  Although the NSAIDs of primary interest for this study were 
diclofenac (which has high COX-2 inhibition) and naproxen (which has low COX-
2 inhibition), we required all subjects to have been prescribed at least one NSAID 
of any type to minimize confounding by indication.  NSAID never-users may 
potentially have had inactive arthritis, incomplete documentation of medications, 
or a contraindication to NSAID use.  Therefore, the risk of MI in NSAID never-
users was expected to be unpredictably but systematically different from the risk 
in SpA or OA patients who were prescribed an NSAID.   
 
Case and control ascertainment.  We identified cases of MI as the first recording 
of an MI Read code by the GP, a definition that had a PPV of 95% in previous 
THIN study.20  In the SpA and OA cohorts separately, each MI case was 
matched to 1–4 control subjects who did not have an MI, according to age (within 
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2 years), gender, and year of diagnosis of SpA or OA. 
 
Exposure assessment.  For each subject NSAID use was categorized as 
“current” if the most recent NSAID prescription was calculated to end 0–180 days 
prior to index date, ”recent” if the prescription ended 180–365 days prior or 
“remote” if more than 365 days prior to the index date.  This approach of 
prescription recency was pioneered by Graham et al. but has since been adopted 
by our research group in the study of rheumatic disease populations.21 22 
Prescription end date was calculated according to details of the prescriptions 
issued by the GP.  In the event that the instructions for a prescription lacked 
detail on the quantity of medication to be used each day, we estimated the daily 
quantity as follows:  for diclofenac, each specific formulation was reviewed and 
an expert clinician reviewed the available quantity frequencies to select the 
frequency that was thought to me most likely; for naproxen the default number of 
daily tablets was two.   
 
Figure 1.  Case-control study design.  The study begins on the right, with selection of MI cases 
and matched controls, who did not have MI.  Subjects’ exposure to NSAIDs was assessed as 
“Current” (within 180 days), “Recent” (180–365 days), or “Remote” (>365 days).  NSAID non-
users were excluded.  Remote NSAID use was considered the referent category.   
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Covariate assessment.  We assessed for the presence of potential confounders 
of the relationship between NSAID use and MI using diagnostic records, 
including any prior diagnosis of hypertension, hyperlipidemia, diabetes mellitus, 
gastrointestinal bleeding, ischemic heart disease and chronic kidney disease.  
We assessed use of medications that are potential confounders, using 
prescription records from the year period preceding the index date.  We included 
use of: aspirin, anti-hypertensives, and lipid lowering agents (statins and 
fibrates). Body mass index (BMI) and smoking status were also considered, and 
classified according to the most recent recording prior to the index date, within 5 
years.  For the primary analysis, missing values of BMI and smoking status were 
imputed using multiple imputation.23   
 
Statistical analysis.  We generated descriptive statistics for MI cases and 
controls, including mean age, sex, prevalence of comorbidities and medication 
use, and BMI and smoking categories.  Statistical comparison between cases 
and controls was not be performed for descriptive statistics.  
 
For the primary analysis, we calculated a crude odds ratio for the odds of current 
NSAID use relative to remote NSAID use for cases and controls.  To adjust for 
potential confounders, a conditional logistic regression model was used, 
adjusting for baseline presence of potential confounders (outlined above), for the 
SpA and OA cohorts separately.  For each odds ratios (OR), we calculated a 
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95% confidence interval (CI) for each category of NSAID exposure (current and 
recent) relative to remote use of any NSAID (the referent).   
To compare the ORs between the SpA and OA cohorts, we calculated the ratio 
of the odds ratios with 95% CI.24  
 
Sensitivity analyses 
To assess the robustness of the primary analysis findings, we conducted several 
sensitivity analyses.  Firstly, because the OA subjects had a mean age more 
than 10 years greater than the SpA subjects, we performed an analysis restricted 
to subjects aged 55–70 years.  Secondly, we re-matched the original SpA cohort 
cases to controls, using all the original matching factors, and additionally 
matching on SpA subtype (AS or PsA; within the SpA cohort only).  We then 
examined the effect estimates within the SpA population, stratified by SpA 
subtype.  Finally, while the primary analysis used imputation for missing data on 
BMI and smoking status, we also performed a complete case analysis, excluding 
any subjects who did not have data on both BMI and smoking.   
All analyses were performed using SAS 9.3 or 9.4 (SAS Institute, Cary, NC).  
 
Results 
Subject characteristics.  From an original SpA cohort of 8140, we identified 115 
MI cases and 455 matched controls. From the OA cohort of 244,399, we 
identified 6287 MI cases and 25164 matched controls.  In each cohort, MI cases 
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had a greater prevalence of traditional MI risk factors, including CKD, diabetes, 
hyperlipidemia, hypertension, IHD, obesity and smoking (Table 1).  MI cases also 
tended to have greater use of medications for treatment of hypertension and 
diabetes, including aspirin, ACE-inhibitors, beta-blockers, and lipid lowering 
agents.  Among subjects in the SpA cohort, disease modifying anti-rheumatic 
drug (DMARD) use was present in 35% of MI cases and 30% of controls.  
Biologic use was rare, as expected, occurring in only 1 SpA control subject.   
 
NSAID prescriptions.  Among subjects with current diclofenac use, the majority 
(92%) were prescribed a daily dosage or 100 mg or more, with 150 mg daily 
being the most common prescription (74%).  The daily dosage or diclofenac was 
100 mg or more in 92% of OA subjects, 95% of AS subjects and 92% of PsA 
subjects, respectively.   For naproxen, the most common daily dosage was 1000 
mg (55%).  The daily dosage was 1000 mg or greater in 56% of OA subjects, 
63% of AS subjects and 72% of PsA subjects.  Among all subjects whose most 
recent prescription was an NSAID other than diclofenac or naproxen, the most 
common drug was ibuprofen (55%), followed by celecoxib (11%), meloxicam 
(10%), rofecoxib (7%), etoricoxib (5%), indomethacin (3%) and etodolac (3%).  
All other NSAIDs accounted for 2% or less of prescriptions.   
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Table 1.   Characteristics of cases and controls derived from the underlying SpA 
and OA cohorts 
 SpA cohort OA cohort 
 Cases Controls Cases Controls 
Subjects (n) 115 455 6287 25164 
Age, mean ± SD 63.0 ± 11.5 62.7 ± 11.4 72.6 ± 10.3 72.5 ± 10.2 
Female 35 (30.4%) 138 (30.3%) 2927 (46.6%) 11716 (46.6%) 
Comorbidities* 
Chronic kidney 
disease 
14 (12.2%) 52 (11.4%) 1043 (16.6%) 3248 (12.9%) 
Diabetes 23 (20.0%) 52 (11.4%) 1153 (18.3%) 3195 (12.7%) 
Gastrointestinal 
Bleeding 
5 (4.3%) 17 (3.7%) 339 (5.4%) 1011 (4.0%) 
Hyperlipidemia 22 (19.1%) 58 (12.7%) 1211 (19.3%) 3898 (15.5%) 
Hypertension 66 (57.4%) 188 (41.3%) 3626 (57.7%) 12491 (49.6%) 
Ischemic Heart 
Disease 
44 (38.3%) 39 (8.6%) 2707 (43.1%) 3048 (12.1%) 
Medication Use*     
Aspirin 29 (25.2%) 71 (15.6%) 2354 (37.4%) 6400 (25.4%) 
ACE-inhibitors 32 (27.8%) 87 (19.1%) 1732 (27.5%) 5568 (22.1%) 
Beta Blockers 19 (16.5%) 66 (14.5%) 1687 (26.8%) 4697 (18.7%) 
Lipid Lowering 
Drugs 
42 (36.5%) 111 (24.4%) 2382 (37.9%) 7956 (31.6%) 
DMARDs 41 (35.7%) 137 (30.1%) 196 (3.1%) 488 (1.9%) 
Biologics 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%) 
BMI*- missing 29 (25.2%) 154 (33.8%) 1580 (25.1%) 7197 (28.6%) 
Underweight 5 (4.3%) 9 (2.0%) 168 (2.7%) 546 (2.2%) 
Normal 15 (13.0%) 64 (14.1%) 1016 (16.2%) 4181 (16.6%) 
Overweight 32 (27.8%) 126 (27.7%) 1929 (30.7%) 7405 (29.4%) 
Obese 34 (29.6%) 102 (22.4%) 1594 (25.4%) 5835 (23.2%) 
Smoking* missing 6 (5.2%) 21 (4.6%) 184 (2.9%) 786 (3.1%) 
Non-smoker 27 (23.5%) 170 (37.4%) 2364 (37.6%) 11428 (45.4%) 
Ex-smoker 46 (40.0%) 183 (40.2%) 2506 (39.9%) 9894 (39.3%) 
Current smoker 36 (31.3%) 81 (17.8%) 1233 (19.6%) 3056 (12.1%) 
Values expressed are N (%) unless otherwise noted.  SpA:  spondyloarthritis, OA:  osteoarthritis, 
DMARDs:  disease modifying anti-rheumatic drugs, BMI:  body mass index.  
*Assessed prior to study entry; comorbidities and any time prior to study, medications within the 
year prior; most recent BMI/smoking status within 5 years 
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Associations of NSAID use with MI. In the primary analysis, among SpA subjects, current diclofenac use was 
associated with an OR of 2.23 (95% CI 1.22–4.05), which after adjustment for covariates, and imputation for 
missing values of BMI and smoking, increased to 3.05 (95% CI 1.48–6.29; Table 2).  Current naproxen use was not 
associated with an increased OR for MI (adjusted OR [aOR] 1.25, 95% CI 0.56–2.78], nor was current or recent 
use of other NSAIDs (aORs 1.32 [0.67–2.60] and 1.05 [0.38–2.92], respectively).   
 
Table 2.  Primary outcome:  Odds of myocardial infarction with current use of diclofenac, naproxen or 
other NSAIDs, and recent use of an NSAID, relative to remote use of NSAIDs, among patients with 
spondyloarthritis and osteoarthritis. 
  SpA OA  
Cases 
(n=115) 
Controls 
(n=455) 
Crude OR aOR* Cases 
(n=6287) 
Controls 
(n=25164) 
Crude OR aOR* 
Current+ 
diclofenac  
25 62 2.23 
(1.2–4.1) 
3.05 
(1.5–6.3) 
843 2981 1.23 
(1.1–1.3) 
1.30 
(1.2–1.4) 
Current  
naproxen  
14 46 1.60 
(0.8–3.2) 
1.25 
(0.6–2.8) 
339 1365 1.06 
(0.9–1.2) 
1.04 
(0.9–1.2) 
Current  
other NSAID  
29 107 1.48 
(0.8–2.6) 
1.32 
(0.7–2.6) 
1224 4491 1.18 
(1.1–1.3) 
1.21 
(1.1–1.3) 
Recent+ 
NSAID  
8 39 1.05 
(0.5–2.4) 
1.05 
(0.4–2.9) 
684 2805 1.05  
(0.96–1.2) 
1.04 
(0.9–1.2) 
Remote+  
NSAID 
39 201 1.0 (ref) 1.0 (ref) 3197 13522 1.0 (ref) 1.0 (ref) 
 
SpA: spondyloarthritis (includes ankylosing spondylitis and psoriatic arthritis), OA:  osteoarthritis, OR: odds ratio, aOR: adjusted OR 
*Adjusted for potential confounders, using imputed BMI/smoking when missing 
+Current use:  prescription end date 0–180 days prior to index date; recent use: 180–365 days and remote use:  >365 days 
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The OR for risk of MI with current diclofenac use was also increased among OA 
subjects, but was lesser in magnitude than that in SpA; crude OR 1.23 (95% CI 
1.12–1.34), aOR 1.30 (1.18–1.43).  Current naproxen was not associated with an 
increased OR, but current use of other NSAIDs was (aOR 1.21, 95% CI 1.11–
1.32) in the OA cohort. 
 
Ratio of ratios.  Using the results from the primary analysis, the ratio of odds 
ratios for current diclofenac (OA as the referent) was 2.35 (95% CI 1.10–4.90), 
suggesting that the risk of MI with current diclofenac use was more than twice as 
great in SpA patients as it was in OA.  When these results were repeated using 
the ORs from the SpA subtype matched analysis, the ratio of ORs was 1.85 
(95% CI 0.90–4.90; Table 3). 
 
Table 3.  Ratio of odds ratios for current diclofenac use in SpA relative to 
OA 
 Original SpA cohort, 
unmatched by SpA 
Subtype 
Sensitivity analysis: SpA 
cohort, 
matched by SpA subtype   
SpA OA SpA OA 
*aOR 3.05 1.30 2.34 1.30 
Ratio of odds 
ratios (95% CI) 
2.35  
(1.1–4.9) 
1.80  
(0.9–4.9) 
 
* From the fully adjusted model including imputed values for BMI and smoking when 
missing 
 
 
Sensitivity analyses.  With restriction to subjects aged 55–70 in both the SpA and 
OA cohorts, the results were not meaningfully changed (Table 4); current 
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diclofenac aORs were: for SpA 3.36 (95% CI 0.9–12.8), and for OA 1.30 (95% CI 
1.1–1.5).  When we re-matched subjects within the SpA cohort based on the SpA 
subtype (AS or PsA) in addition to the other matching factors, the crude OR for 
diclofenac use within the whole SpA sample remained similar (OR 2.08 versus 
2.23 with the original design), however the aOR was only 2.34 (95% CI 1.1–4.9; 
original aOR 3.05).  When stratified by SpA subtype, the crude and adjusted ORs 
for current diclofenac were similar in the subtypes, but confidence intervals were 
much wider, due to smaller numbers (8 AS cases and 17 PsA cases).  For AS, 
aOR for current diclofenac use was 1.93 (95% CI 0.2–14.9) and for PsA, aOR 
1.79 (95% CI 0.7–4.5) (Table 4).  Interestingly, naproxen continued to have no 
association with MI among AS subjects, but had an increased point estimate 
(with wide CI) among PsA subjects (aOR 2.59, 95% CI 0.89–7.52).  When we 
restricted analyses to only subject with complete data on BMI and smoking, the 
results were not meaningfully changed for either SpA or OA subjects (data not 
shown). 
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Table 4.  Sensitivity analyses: (A) Age restricted to 55–70 years, (B) SpA cases and controls rematched and 
stratified by SpA subtype.  Odds of myocardial infarction with current use of diclofenac, naproxen or other NSAIDs 
relative to remote use of NSAIDs. 
 
A.  Age-restricted to 55–70 years 
  SpA OA  
Cases 
(n=115) 
Controls 
(n=455) 
Crude OR aOR* Cases 
(n=6287) 
Controls 
(n=25164) 
Crude OR aOR* 
Current+ 
diclofenac  
11 29 2.13  
(0.9–5.1) 
3.36  
(0.9–12.8)  
349 1263 1.19  
(1.0–1.4) 
1.30  
(1.1–1.5) 
Current  
naproxen  
8 26 1.64  
(0.6–4.2) 
1.11  
(0.3–4.5) 
144 595 1.02  
(0.8–1.3) 
0.95  
(0.8–1.2) 
Current  
other NSAID  
14 49 1.55  
(0.7–3.4) 
1.60  
(0.5–5.1) 
394 1517 1.12  
(1.0–1.3) 
1.15  
(1.0–1.3) 
Recent+ 
NSAID  
3 16 0.95  
(0.2–3.8) 
0.59  
(0.1–4.2) 
250 963 1.11  
(1.0–1.3) 
1.11  
(0.9–1.3) 
Remote+  
NSAID 
18 96 1.0 (ref) 1.0 (ref) 898 3802 1.0 (ref) 1.0 (ref) 
 
B.  SpA Subtype Matched and Stratified 
 Ankylosing Spondylitis Psoriatic Arthritis 
Current+ 
diclofenac  
8 14 2.83 
(0.9–8.7) 
1.83  
(0.2–14.9) 
17 49 1.76  
(0.9–3.6) 
1.79 
(0.7–4.5) 
Current  
naproxen  
3 14 1.14  
(0.3–4.9) 
0.32  
(0.02–4.9) 
11 27 2.09  
(0.9–4.9) 
2.59 
(0.9–7.5) 
Current  
other NSAID  
12 38 1.60  
(0.6–4.1) 
0.82  
(0.1–5.9) 
17 81 1.05  
(0.5–2.1) 
0.85 
(0.4–2.0) 
Recent+ 
NSAID  
1 16 0.33  
(0.04, 2.8) 
** 7 22 1.55  
(0.6–4.0) 
1.38 
(0.4–4.4) 
Remote+  
NSAID 
11 53 1.0 (ref) 1.0 (ref) 27 131 1.0 (ref) 1.0 (ref) 
 
SpA: spondyloarthritis (includes ankylosing spondylitis and psoriatic arthritis), OA:  osteoarthritis, OR: odds ratio, aOR: adjusted OR 
*Adjusted for potential confounders, using imputed BMI/smoking when missing 
+Current use:  prescription end date 0–180 days prior to index date; recent use: 180–365 days and remote use:  >365 days 
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Discussion 
 This nested case-control study performed using general practitioner 
electronic medical records, demonstrates an increased risk of MI among SpA 
patients using diclofenac.  Relative to patients with OA, SpA patients appeared to 
have about twice the risk of MI with diclofenac use.  This novel design used in 
this study, comparing current NSAID users to remote NSAID users, minimizes 
confounding by indication by comparing diclofenac users to remote NSAID users, 
all of whom were judged to have an indication for prescription NSAID use by their 
GP.  While these findings warrant confirmation in other large SpA populations, 
the increased risk of MI with current diclofenac use and the absence of an 
increased risk among current naproxen users, has important implications for 
clinicians who prescribe or recommend NSAIDs to SpA patients.  Given that 
NSAIDs are recommended as first-line therapy in both North America and 
Europe, there are hundreds of thousands of SpA patients whose MI risk may be 
reduced by treatment with naproxen rather than diclofenac.   
 
While the risk of MI with specific NSAIDs has been studied in the general 
population, little data exists among patients with inflammatory arthritis, such as 
SpA. One cohort study, in rheumatoid arthritis, found that the risk of 
cardiovascular disease (combined endpoint of MI, stroke and cardiovascular 
mortality) was lower in RA than in controls without RA. Specific NSAIDs such as 
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rofecoxib and diclofenac were associated with increased risk, but others were 
not.25 
 
In ankylosing spondylitis, Essers and others performed a cohort study using the 
British Clinical Practice Research Datalink (CPRD), a large medical records 
database with 60% overlap with THIN.  The results indicate no increased rate of 
MI among AS patients overall.  The investigators did find an increased incidence 
rate of ischemic heart disease in women (HR 1.88 [95% CI 1.22–2.90]), which 
was attenuated after NSAID use was adjusted for in the multivariable model (HR 
1.57 [95% CI 0.99–2.48]).  These results are consistent with the current study 
findings that the selected NSAIDs do increase heart disease risk.26 
 
In a cohort study using the Ontario health administrative data, the effect of 
NSAIDs on cardiovascular mortality was assessed in a subset analysis among 
those aged 66 and older. 4  This older adult subset was selected because 
prescription data was limited to this group.  Authors report the multivariable 
adjusted HR of 0.1 with NSAID use (95% CI 0.01–0.61) and broadly state that 
“lack of NSAID exposure” is a risk factor for vascular death. This finding, that 
NSAID use is associated with 90% reduction in cardiovascular mortality in this 
population lacks face validity.  But more importantly, the study design raises 
concern for prevalent user bias; that persons with AS who survive to late 
adulthood without a complication from or contraindication to NSAID use reflect 
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the healthiest stratum of AS patients.  The same analysis, demonstrating no 
increased mortality risk with statin use, hypertension, CKD or cancer, illustrates 
the same bias.  In contrast to the Toronto study, the present study is not limited 
to older adults and therefore is less likely to suffer from bias due to prevalent 
NSAID use.  In fact, our analysis restricted to persons aged 55–70 years 
demonstrates the findings of the Toronto study should not be assumed to hold 
true in a younger SpA population.   
 
The present study has several limitations and strengths that warrant discussion. 
Although this study applied validated algorithms for identification of SpA, it was 
not possible to confirm SpA diagnosis for included subjects.  However we expect 
that any misclassification non-diseased persons as having SpA subjects would 
bias study results toward the null.  Additionally, while prescription data is detailed 
in THIN, we cannot know if patients adhered to therapy. Some patients may take 
NSAIDs inconsistently, only on an as-needed basis for pain, and the pattern of 
use may differ according to the indication for use (SpA versus OA). To provide 
conservative estimates for this study, this study assumed complete medication 
adherence, using an estimate of the shortest possible exposure window for a 
given prescription. This may have led to misclassification of some current users 
as recent or remote users, potentially overestimating effects in recent or remote 
use categories and biasing results for current NSAID users toward the null.  
Finally, confounding by indication still remains a potential concern in that an 
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NSAID prescription may indicate a period of pain or increased disease activity, 
and it may be that painful condition or disease activity that truly puts a study 
subject at risk.  Because it was not possible to assess disease activity within this 
study, we consider the results of this study to be exploratory or suggestive of an 
increased risk of MI with diclofenac, but not alone enough to change treatment 
guidelines. Finally, the ratio of odds ratios, indicated diclofenac use had 
approximately twice the risk of MI among SpA relative to OA, but failed to reach 
statistical significance in our sensitivity analysis, and therefore warrant further 
investigation.   
 
This study has several strengths worth noting.  Firstly, our use of a large, general 
practitioner-derived database reflects real world NSAID use and real world risk, 
in contrast to the relatively great drug adherence and highly selected population 
that would be present in medication trials.  Secondly, the requirement that all 
included subjects had at least one NSAID prescription likely reduces confounding 
by indication, at least to some degree, and offers an advantage over previous 
studies that included SpA subjects who had not received NSAIDs at all.   
While the primary outcome of MI was established through the use of diagnostic 
codes, the PPV using this method was high in a previous validation study, and an 
internal validation study of MI cases confirmed MI in 89% of cases.   
Additionally, our series of sensitivity analysis, all confirming the primary finding of 
increased risk with diclofenac use in SpA with variations in the study population 
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and design, supports that our primary results are robust given the assumptions 
made in our analytical approach.   
 
Conclusions 
This study found that among SpA patients, current use of diclofenac was 
associated with two- to three-fold risk of MI relative to remote use of any NSAID.  
The risk associated with diclofenac in SpA was approximately double the risk in 
OA patients.  Current naproxen use, on the other hand, did not increase MI risk 
in SpA or OA, though effects should be further investigated in SpA subtypes.  
These results suggest that diclofenac use contributes to risk of MI in SpA 
patients, and suggests that in the SpA population, overall MI risk could be 
lowered through preferential use of naproxen.   If confirmed in other large SpA 
data sets, these findings may motivate a change in practice guidelines to 
recommend naproxen as the preferred first-line NSAID. 
 
.
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